Antibody Engineering at the Millennium

Gavilondo, Jorge V.; Larrick, James W.

doi:10.2144/00291ov01

Cited by 104 publications

(49 citation statements)

References 129 publications

(127 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…L'ingénierie des anticorps est une approche innovante et les perspectives de développement industriel semblent prometteuses. Selon une récente étude, sept préparations thérapeu-tiques seraient en évaluation clinique chez six industriels différents [29]. L'amélioration constante de systèmes d'expression de protéines recombinantes assurant des rendements de synthèse élevés, une forte affinité et une parfaite glycosylation, devrait permettre d'élaborer de nouveaux anticorps anti-infectieux, efficaces et peu coûteux, pour lutter contre des maladies infectieuses, en particulier respiratoires, émer-gentes ou résistantes aux agents antimicrobiens.…”

Section: Immunothérapie Des Infections Respiratoires Par Anticorps Mounclassified

Immunoprophylaxie des infections respiratoires

2004

View full text Add to dashboard Cite

Section: Immunothérapie Des Infections Respiratoires Par Anticorps Mounclassified

Immunoprophylaxie des infections respiratoires

2004

View full text Add to dashboard Cite

“…The most advanced product to date is an antiStreptococcus mutans secretory antibody for the prevention of dental caries that is currently in Phase II clinical trials. Plants offer the only viable, large-scale production system for this antibody (Gavilondo andLarrick 2000, Larrick andThomas 2001). Links to further information and a comprehensive table of antibody targets in clinical trials can be accessed through the Seed Biotechnology Center at the University of California, Davis.…”

Section: T H E R a P E U T I C P R O T E I N S Antibodiesmentioning

confidence: 99%

Production of Therapeutic Proteins in Plants

Thomas¹

2002

View full text Add to dashboard Cite

Until recently, pharmaceuticals used for the treatment of diseases have been based largely on the production of relatively small organic molecules synthesized by microbes or by organic chemistry. These include most antibiotics, analgesics, hormones, and other pharmaceuticals. Increasingly, attention has focused on larger and more complex protein molecules as therapeutic agents. Proteins are large molecules composed of long chains of subunits called amino acids (see Suslow, Thomas, and Bradford 2002). Just as words are composed of the 26 letters of the alphabet, proteins are composed of different combinations of the 20 or so amino acids, except that the length of proteins is often 100 to 1,000 amino acids ("letters") long. The structure and functionality of a given protein is determined by its sequence of amino acids, which, in turn, determines its three-dimensional conformation, or structure. Internal bonds (sulfur and hydrogen bonds) among the amino acids give the protein its final shape and form. Complex proteins undergo further processing such as the addition of phosphate groups (phosphorylation) or carbohydrate molecules (glycosylation), which modify the proteins' functions. Information stored in DNA directs the protein-synthesizing machinery of the cell to produce the specific proteins required for its structure and metabolism. Since proteins play critical roles in cell biology, they have many potential therapeutic uses in preventing and curing diseases and disorders. The first protein used to treat disease was insulin, a small peptide that revolutionized the treatment of diabetes. In addition, the antigens used in vaccinations to induce immune responses are often proteins.While short peptide chains (containing fewer than 30 amino acids) can be synthesized chemically, larger proteins are best produced by living cells. The DNA that encodes the instructions for producing the desired protein is inserted into cells, and as the cells grow they synthesize the protein, which is subsequently harvested and purified. Since 1982, more than 95 therapeutic proteins, or peptides ("biologics"), have been licensed for production using bacterial, fungal, and mammalian cells grown in sterile cultures, and hundreds of additional therapeutic proteins are currently being developed and tested. In fact, many analysts anticipate that in the near future the capacity of cell culture facilities will fall far short of demand, as augmenting cell culture facilities requires large investments in buildings and equipment. Recently, transgenic (i.e., plants engineered to produce specific proteins) plant expression systems (Suslow, Thomas, and Bradford 2002) were developed as alternative sources for the production of biologics, known as plant-made pharmaceuticals, or PMPs. In general, the use of plants means a lower cost of production and easier expansion for large-volume production than cell culture systems. Instead of a large capital investment in cell culture facilities, plant production systems can be expanded simply by growing and harve...

show abstract

“…Targeted therapy using specific monoclonal antibodies (mAb) offers an alternative for the treatment of diverse chronic diseases such as autoimmune disease or cancer [1]. Initial developments used mouse monoclonal antibodies, nevertheless with very poor clinical achievement, undesired anti-mouse response; low half-lives in humans and lack of efficacy of the Fc functions were the main drawbacks [2][3][4].…”

Section: Introductionmentioning

confidence: 99%

Generation of a Chimeric Antibody against a Synthetic Peptide Derived From IL-23p19 with Potential Therapeutic Application

Pérez-Etcheverry

Carmen

2017

IRA-JAS

View full text Add to dashboard Cite

Aim: To construct an express a mouse-human chimeric antibody against IL-23p19 using a synthetic peptide as immunogen.Methods: Immunization of mice with a synthetic peptide derived from the IL-23p19 sequence and generation of hybridoma secreting specific antibodies. The chimeric antibody was created using two eukaryotic plasmid constructions; one of them carrying the light mouse-human chain and the other the heavy mouse-human chain. CHO-K1 cells were cotransfected with both plasmids and stable transfectants were grown in selective culture medium.Results: A chimeric version of anti-IL-23p19 was successfully constructed and expressed in eukaryotic cells. The expressed chimeric antibody showed specific recognition not only of the peptide used as immunogen but also the subunit p19 and the complete interleukin Il-23.Conclusion: A Chimeric antibody that was developed against a synthetic peptide, which is able to recognize the parent protein IL23 biologically active, could be developed into a targeted therapy in diseases with chronic inflammation.

show abstract

Antibody Engineering at the Millennium

Cited by 104 publications

References 129 publications

Immunoprophylaxie des infections respiratoires

Immunoprophylaxie des infections respiratoires

Production of Therapeutic Proteins in Plants

Generation of a Chimeric Antibody against a Synthetic Peptide Derived From IL-23p19 with Potential Therapeutic Application

Contact Info

Product

Resources

About